Genmab — Marts 2017
-
-
Skal man købe i dag, eller falder de, de næste par dage? (ved godt i ikke er spåkoner
) -
Nordea: We shave 2% from ou
r DCF-based target price
to DKK 1,570 (1,595) and we would recommend aggressively
adding to positions if the stock takes a hit of
more than 3-4%. We reiterate our Buy rating on Genmab.
This news prompts us to shave just
2% from our DCF-based target -
-
"Kære læser. Det er i strid med lov om ophavsret at kopiere og videresende artikler uden brug af det officielle link: http://borsen.dk/nyheder/virksomheder/artikel/1/342690/genmab-boss_til_aktionaerer_i_kan_ikke_forlange_midler_over_standard_uden_risici.html#ixzz4ctBXTLKc
Genmab-boss til aktionærer: I kan ikke forlange midler over standard uden risici
" -
Min mavefornemmelse er fuldstændig splittet. Derfor søger jeg råd hos jer. Bibob har du suppleret?
-
Så din mavefornemmelse siger køb?
-
Ingen tvivl om, at jeg skal supplere. Jeg ved bare ikke, om det skal være i dag, eller vente. Det kunne godt være, at den bare får tæsk i dag, og stille kommer tilbage
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind